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Abstract
Background: Tachykinins substance P, neurokinin A and neurokinin B seem to account for asthma
pathophysiology by mediating neurogenic inflammation and several aspects of lung mechanics. These
neuropeptides act mainly by their receptors NK1, NK2 and NK3, respectively which may be targets for new asthma
therapy.
Methods: This review systematically examines randomized controlled trials evaluating the effect of tachykinins
receptors antagonism on asthma. Symptoms, airway inflammation, lung function and airway inflammation were
considered as outcomes. We searched the Cochrane Airways Group Specialized Register of Asthma Trials, Cochrane
Database of Systematic Reviews, MEDLINE/PubMed and EMBASE. The search is as current as June 2010. Quality
rating of included studies followed the Cochrane Collaboration and GRADE Profiler approaches. However, data
were not pooled together due to different measures among the studies.
Results: Our systematic review showed the potential of NK receptor antagonist to decrease airway responsiveness
and to improve lung function. However, effects on airway inflammation and asthma symptoms were poorly or not
described.
Conclusion: The limited available evidence suggests that tachykinin receptors antagonists may decrease airway
responsiveness and improve lung function in patients with asthma. Further large randomized trials are still
required.
Background
A sharp increase in the prevalence, morbidity, mortality,
and economic burden associated with asthma over the
last 40 years, particularly in children is occurring.
Approximately 300 million people worldwide have
asthma, and its prevalence increases by 50% every dec-
ade [1]. Because no asthma definition exists, an opera-
tional definition was proposed by the Global Initiative
for Asthma: a chronic inflammatory disorder of the air-
ways associated with airway hyperesponsiveness that
leads to recurrent episodes of wheezing, breathlessness,
chest tightness, and coughing [1]. Therefore, asthma is a
phenotypically heterogeneous disorder and, over the
years, many different clinical subtypes of asthma have
been described.
Recently, a model of interaction between different
pathophysiologic mechanisms known to affect asthma
phenotype was suggested [2]. This is of particular
importance not only to recognize asthma as a complex
disease for which different endogenous and exogenous
factors may account, but also for emphasising the need
of a precise definition of the asthma phenotype as a tool
for improved asthma care. Despite major advances in
understanding the pathogenesis of asthma and improve-
ments in asthma drugs, the accompanying benefits have
been less than expected. Drug strategies for asthma have
been based on the premise that symptoms derive
directly and immediately from airway inflammation
focusing on the development of anti-inflammatory
drugs, particularly steroids that show broad-spectrum
inhibitory activity against a wide range of effector cells
and their products. Evidence for an interaction between
chronic inflammation and neural dysfunction points to
an involvement linking the nervous and the immune
system in the airways [3]. In this context, neuropeptides
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and neurotrophins have been recognized as key media-
tors of neuro-immune interactions [3] and investigation
regarding the development of pharmacological com-
pounds specifically targeting these molecules could be of
interest in asthma.
Tachykinins include a family of neuropeptides with a
wide range of actions in human body [4]. The most rele-
vant are substance P, neurokinin A (NKA) and neuroki-
nin B (NKB) and act mainly by their receptors which
are NK1, NK2 and NK3, respectively [5]. Interestingly,
tachykinins are potent mediators of a number of func-
tions in the airways [6]. Within human airways, sub-
stance P and NKA are the predominant neuropeptides
released from nonadrenergic-noncholinergic system by
mechanical, thermal, chemical or inflammatory stimuli.
NK3 receptors have been only recently considered in
studies of airway regulation in health and in disease [7].
This is due to the observation that NKB, the most
potent endogenous ligand for the NK3 receptor, is not
readily localized to the airway nerves. In addition, con-
trasting the effects of NK1 and NK2 receptor activation
in the airways, which induce pronounced and thus read-
ily quantifiable effects in the lungs (e.g. bronchospasm,
vasodilatation, vascular leakage, mucus secretion), the
actions of NK3 receptor-selective agonists are mostly
subtle and not simply measured with commonly used
airway function measures [7].
Recent findings point to tachykinergic systems as pro-
mising targets of novel clinical agents. In asthma, the
modulation of their receptors appear to influence a vari-
ety of pathological symptoms and processes such as
inflammation [4]. However, improved therapeutic strate-
gies can only be delineated if clinical effects are achieved
by well-designed randomized controlled trials. There-
fore, in an effort to assemble the clinical effects of
tachykinin receptors modulation on asthmatic patients
the authors conducted this systematic review.
Methods
Studies, participants, interventions and outcomes
The review was restricted to randomized controlled
clinical trials and controlled trials, which studied the
effect of tachykinin receptor antagonists on asthma
related outcomes. Participants were adults or children
with a medical diagnosis of asthma. All health-care set-
tings were considered eligible and no restrictions for
gender were made. The selected outcome measures
were: symptoms, adverse events of the treatments, lung
function, airway responsiveness and inflammation.
Search strategy
An initial search was carried out using the Cochrane
Airways Group Specialized Register of asthma trials and
EBM Reviews - Cochrane Database of Systematic
Reviews. Additional and separate searches were carried
out on MEDLINE (1966-2010), EMBASE (1980-2010)
and PubMed. The subject-specific search terms were
“tac1r”, “tac2r” “tac3r”, “tachykinins”, “tachykinins
antagonists” “NK-1R”, “NK-2R”, “NK-3R”, “substance P”,
“neurokinin A”, “neurokinin B”, “asthma”. The reference
lists of all primary studies were reviewed to identify
trials not captured by electronic and manual searches.
All titles and abstracts identified by the search that
appeared relevant were selected for full text review.
Update searches have been run up to June 2010.
Data collection and analysis
Abstracts of articles identified were viewed and articles
that appear to fulfil the inclusion criteria were retrieved
in full. Two reviewers (RR and NC) applied the inclu-
sion criteria independently and where disagreement
occurred they were resolved by consensus. Data were
extracted by one reviewer (RR) and checked by other
(AM). The methodological quality of the included trials
was assessed with particular emphasis on allocation con-
cealment and randomization, which was ranked using
the Cochrane Collaboration and GRADE Profiler
approaches [8]. This systematic review was in agreement
with the PRISMA guidelines [9]. Meta-analysis was not
conducted due to small number of included trials and
heterogeneity across studies.
Results
Based on title, nineteen studies were identified as poten-
tially relevant. However, based on abstract, only seven
studies appeared to meet the inclusion criteria and their
full text was obtained (Figure 1). Therefore, we included
7 studies comprising the use of five tachykinin receptors
antagonists: NK-2 in two [10-12], NK-1/NK-2 in four
[11,13-15] and NK-1/NK-2/NK-3 in other one [16],
referring to a total of 98 subjects (Table 1). All studies
used different doses of tachykinin receptors antagonists.
Regarding treatment dosages, 5 studies used single-
doses [11-13,15,16] while in 2 studies doses of antago-
nists were given during 2 and 9 consecutive days
[10,14]. Antagonists were administered by inhalation in
3 studies [10,15,16] and orally in 4 studies [11-14].
None of the studies reported changes in asthma symp-
toms as an outcome.
Reviewer’s judgments about risk of bias for each study
was summarized in Figure 2. As shown in Figure 3,
methodological quality of the included trials was graded
as very low (Figure 2). Data extraction from included
studies was summarized in Table 2.
Airway responsiveness
Five of the seven studies reported a decreased in airway
responsiveness with the use of tachykinin receptors
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antagonists. However, this effect seemed to be dose
dependent since in the study from Shelfhout the
improvement of this outcome was not seen for the low-
est dose tested [11]. These studies show, first, these
drugs are indeed tachykinin receptors antagonists, and
secondly, given the very modest shifts in the concentra-
tion response curves, nearly all of these drugs were
underdosed.
Lung Function
Four studies reported lung function as an outcome. All
but one failed to show significant effects with tachyki-
nin receptors antagonists treatments [10,14-16]. How-
ever, in the study from Boot et al. [13] NK-1/NK-2
antagonist administration reverted the NKA-induced
bronchoconstriction.
Airway inflammation
Only one study reported airway inflammation as an out-
come [13]. In this study, authors concluded that airway
inflammation evaluated either by changes in exhaled
nitric oxide or sputum cells counts was not improved
after a dual NK1/NK2 antagonist [13].
Figure 1 Flowchart of selection process.
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• Decreased airway responsiveness
• Inhibition of bronchoconstriction
Schelfhout et
al., 2006 [16]
• Multi- center, RCT,
double-blind, crossover
• 15 subjects (7 females);
mean age 30 yr
• 200 mg CS-003 (triple NK-1/
NK-2/NK-3 receptor




• Decreased airway responsiveness
Joos et al.,
2004 [15]
• Multi- center, RCT,
double-blind, crossover
• 18 males; mean age
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• 10 atopic non-smoking
subjects (2 females);
mean age 27 yr
• 4 mg FK224 (dual NK-1/NK-2
receptor antagonist) inhaled





Summary • 98 young adults (24
females, 74 males)
• Seven different antagonists
acting on NK-1R, NK-2, NK-3 in
mono, dual or triple
combinations.
• Airway responsiveness
to NK antagonist, lung
function and airway
inflammation.
• Five studies showed positive effects on
airway responsiveness and/or lung function
and two studies failed to demonstrate effects
on asthma outcomes.
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Adverse events
Adverse events were only considered as an outcome in
three studies [11,13,15]. In the study from Boot et al.
[13] adverse events were reported as transient self-limit-
ing bronchospasm starting within 12 minutes after drug
inhalation (8 patients under NK-1/NK-2 antagonist and
4 patients under placebo), headache (5 patients under
NK-1/NK-2 antagonist and 3 patients under placebo),
and self-limiting dyspneia (2 patients under NK-1/NK-2
antagonist and 5 patients under placebo). Shelfhout et
al. [11] reported no serious adverse effect with the NK-
1/NK-2 antagonist studied. In the study from Joos et al.
[15] was reported that 4 patients referred fatigue, head-
ache, aggravated asthma, cough and wheezing. However,
as no changes in laboratory parameters were observed
authors concluded that these events were not related to
the NK-1/NK-2 antagonist tested.
Discussion
Our systematic review showed: first, the use of NK
receptor antagonist decreases airway responsiveness and
may improve lung function; secondly effects on airway
inflammation and asthma symptoms have been poorly
or not addressed at all. It must be noted that these con-
clusions are limited by different interventions, doses,
Figure 2 “Risk bias” summary: reviewer author’s judgements
about each risk of bias item for included studies.
Figure 3 Tachykinin receptors antagonists compared to placebo for asthma grading evidence.
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route of administration, schedules and samplings, as well
as patient characteristics. Nevertheless, our review was
strengthened by the use of a complete search strategy
and the omission of relevant studies seems unlikely.
The most important limitation of our review was the
relatively small number of well-designed, adequately
powered studies reporting all outcomes of interest.
Additional limitations were: each of seven studies used
a different drug, most of these studies failed to docu-
ment adequate dosing, and nearly every study targeted
a different combination of the NK1, NK2 and NK3.
The effectiveness of tachykinin receptors antagonism
on cough and chest tightness was not reported. More-
over, airway inflammation was only discussed in one
study. As an inflammatory condition, evaluation of the
effect of drugs in airway inflammation is a major out-
come in asthma. Few studies analysed drug safety and
reported side effects. However, the undesired effects
observed seemed to be not related to the use of
antagonists. Synthesis of the literature with such few
studies was difficult because a single study may affect
the outcomes. In this situation, heterogeneity may be
Table 2 Effect of tachykinin receptors antagonism on asthma outcomes
Control Treated
Outcome N Mean(SD) N Mean(SD) p
• AIRWAY RESPONSIVENESS:
Log PC35 sGaw NKA mol/ml
FK224 (NK-1R/NK-2R antagonist) 10 -6.04(0.18) 10 -6.19(0.23) n.s.
Joos et al, 1996
PC20-AMP mg/ml
SR 48968C (NK-1R/NK2R antagonist)
Kraan et al, 2001 12 1.46(1.11) 6 1.25(0.98) n.s.
Log10PC20-NKA mol/ml
MEN 11420 (NK-2R antagonist)
Shelfhout et al, 2009 12 -6.38(0.26) 12 -6.92(0.25) 0.028
AVE 5883 (NK-1R/NK-2R antagonist)
Boot et al, 2007 19 -6.40(0.12) 19 -6.74(0.12) 0.004
CS-003 (NK-1R/NK-2R/NK-3R antagonist)
Schelfhout et al, 2006 15 -5.92(0.83) 15 -6.99(0.66) <0.05
DNK 333 (NK-1R/NK-2R antagonist)
Joos et al, 2004 18 -5.60* 18 -6.8* <0.001
SR 48068 (NK-2R antagonist)
Schoor et al, 1998 12 -7.02(0.28) 12 -7.64(0.19) 0.05
• LUNG FUNCTION:
FEV1 (% fall)
AVE 5883 (NK-1R/NK-2R antagonist)
Boot e tal, 2007 19 145.5(11.7) 19 116.2(11.7) 0.01
SR 48968C (NK-1R/NK2R antagonist)
Kraan e tal, 2001 12 81(4) 6 78(3) n.s.
FEV1 (L)
CS-003 (NK-1R/NK-2R/NK-3R antagonist)
Schelfhout e tal, 2006 15 3.34(0.62) 15 3.25(0.71) n.s.
FK224 (NK-1R/NK-2R antagonist)
Joos e tal, 1996 10 3.66 × 10-3(0.25) 10 3.67 × 10-3 (0.21) n.s.
• AIRWAY INFLAMMATION:
Eosinophils %
AVE 5883 (NK-1R/NK-2R antagonist)
Boot e tal, 2007 19 4.86(1.75) 19 3.33(1.58) n.s.
eNO ppb
AVE 5883 (NK-1R/NK-2R antagonist)
Boot e tal, 2007 19 37.64(6.40) 19 43.44(6.57) 0.32
* 95% Confidence Interval for the difference in Log10PC20-NK, 0.841-1.616.
SP - substance P; eNO - exhaled nitric oxide; n.s. - reported as not significant.
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introduced and publication bias may be not easy to
detect.
Selective tachykinin receptors antagonists tested on
guinea pigs have been shown to inhibit the late allergic
and airway hyperesponsiveness and reduce eosinophilic
infiltration and vascular permeability [8,17,18]. These
models showed promising effects of dual and triple
antagonists in reducing cough and vascular hyperperme-
ability and inhibiting airway hyperesponsiveness and
bronchoconstriction. Similar results were observed in
studies using ferrets and mice providing additional evi-
dence in reducing mucus production [3,19]. However, as
for other studies involving animals, the extrapolation for
humans has been difficult.
Playing substance P the more relevant role in allergen-
induced airway inflammation, the lack of effectiveness in
reducing airway hyperesponsiveness may be due to com-
promising of results by testing antagonists’ protection
against NKA inhalation. It is recognized that substance
P, acting through its NK-1 receptor, induces broncho-
constriction and airway hyperesponsiveness, with asth-
matics being more sensitive [5,15]. Acting through its
NK-2 receptor, inhaled NKA had been shown to be
more responsible for cause bronchoconstriction [16].
Lack of efficacy in other studies may also be explained
by requirement of different concentrations of antago-
nists to inhibit bronchoconstriction.
The use of tachykinin receptors antagonists in dual
or triple combination rather than one antagonist alone
may be regard as a more efficient way of improve
asthma outcomes. However, the use of these antago-
nists in combination does not allow us to determine
the relative contribution of each tachykinin receptor
subtype to bronchoconstrictor effect of NKA and SP in
asthma. In fact, these receptors have very different
effects on airway cells (Table 3), airway vascular
smooth muscle and central nervous system reflexes.
Future investigation should compare the use of NK-1
and NK-2 receptors antagonists alone and in combina-
tion in order to set the relative contribution of NKA
and SP antagonism in asthma. Furthermore, it seems
imperative to gain more insight into the role of
tachykinin receptors pathways as well as into the effec-
tiveness of their antagonisms on asthma related symp-
toms like cough and chest tightness.
Conclusions
Overall we conclude that the number of studies on
tachykinin receptors modulation in asthma is very small
and limited both in sample size and patients characteris-
tics, as well as in asthma outcome results. However, evi-
dence on the role of tachykinin receptors antagonism in
asthma has been gathered and their potential to regulate
some airway functions has been recognized. Longer ran-
domized trials standardized rating scales and outcome
measures, at similar time periods and with similar
antagonists are required. This further research will also
be important to allow investigators to further define the
role of SP and NKA in asthma pathogenesis.
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